BIBLIOGRAPHIC RECORD

Discovery of NLX-266, an Orally Available and Metabolically Stable ERK1/2-Biased 5-HT<sub>1A</sub>R Agonist with Superior Antidepressant and Antiparkinsonian Activity.

This record contains bibliographic metadata. Open the linked source to check the work; the record does not include its full text.

Recorded authors
Joanna Sniecikowska; Monika Gluch-Lutwin; Adam Bucki; Beata Gryzlo; Krzysztof Wieckowski; Justyna Godyn; Anna Wieckowska; Agata Siwek; Magdalena Jastrzebska-Wiesek; Anna Partyka; Agnieszka Cios; Anna Wesolowska; Adrian Newman-Tancredi; Marcin Kolaczkowski
Source of metadata
PubMed
Year recorded
2025

Public identifiers and source

Open the source record

Reference

Joanna Sniecikowska; Monika Gluch-Lutwin; Adam Bucki; Beata Gryzlo; Krzysztof Wieckowski; Justyna Godyn; Anna Wieckowska; Agata Siwek; Magdalena Jastrzebska-Wiesek; Anna Partyka; Agnieszka Cios; Anna Wesolowska; Adrian Newman-Tancredi; Marcin Kolaczkowski. (2025). Discovery of NLX-266, an Orally Available and Metabolically Stable ERK1/2-Biased 5-HT<sub>1A</sub>R Agonist with Superior Antidepressant and Antiparkinsonian Activity. https://pubmed.ncbi.nlm.nih.gov/40267318/

Reference assembled from the available metadata. Check and cite the original publication before reusing a claim.

Permanent record URL: https://brain.psiconautica.org/en/documentos/d-6369d229a80e7b46648e482bc3e1c4b2/